National Health Investors Earnings Call Transcripts
Fiscal Year 2025
-
Normalized FFO per share grew 8.9% in Q4 and 10.6% for 2025, driven by strong SHOP segment performance and record investment activity. 2026 guidance anticipates continued SHOP growth, $230M in new investments, and a focus on capital recycling and margin expansion.
-
Third quarter results exceeded expectations with strong SHOP NOI growth, raised guidance, and robust investment activity. Liquidity and leverage remain favorable, while legal and competitive risks are being actively managed.
-
Second quarter results surpassed expectations, with strong SHOP NOI growth and raised 2025 guidance. Liquidity and balance sheet remain robust, supporting accelerated acquisitions and a dividend increase. SHOP transitions and strategic hires position the company for continued growth.
-
Q1 2025 results exceeded expectations with strong acquisition activity, higher rent collections, and raised guidance for FFO and FAD. SHOP segment showed NOI growth and improved occupancy, while the balance sheet remains strong and the investment pipeline robust.
Fiscal Year 2024
-
Q4 and full-year 2024 results surpassed expectations with strong rent and NOI growth, robust investment activity, and improved leverage. 2025 guidance projects continued FFO and FAD growth, with $225 million in new investments and 12%-15% SHOP NOI growth.
-
Q3 2024 saw strong portfolio fundamentals, with sequential improvements in occupancy and EBITDA coverage, robust investment activity, and a tightened SHOP NOI growth outlook. Net income and FFO per share declined year-over-year, but FAD and SHOP NOI posted solid gains.
-
Q2 2024 results exceeded expectations with strong FFO and FAD growth, robust SHOP performance, and a raised 2024 outlook. Investment activity and pipeline are accelerating, supported by a solid balance sheet and favorable market trends.